Cost-effectiveness analysis of PCV20 to prevent pneumococcal disease in the Canadian pediatric population

This study assessed the cost-effectiveness of the 20-valent pneumococcal conjugate vaccine (PCV20) in Canadian infants aged <2 years versus the standard of care (SoC), a 13-valent pneumococcal conjugate vaccine (PCV13), or a potential 15-valent pneumococcal conjugate vaccine (PCV15). A decision-a...

Descripción completa

Detalles Bibliográficos
Autores principales: Lytle, Derek, Grajales Beltrán, Ana Gabriela, Perdrizet, Johnna, Ait Yahia, Nassim, Cane, Alejandro, Yarnoff, Benjamin, Chapman, Ruth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2023
Materias:
Pneumococcal
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10543337/
https://www.ncbi.nlm.nih.gov/pubmed/37771288
http://dx.doi.org/10.1080/21645515.2023.2257426

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10543337/
https://www.ncbi.nlm.nih.gov/pubmed/37771288
http://dx.doi.org/10.1080/21645515.2023.2257426

Ejemplares similares